Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosciens Biopharma (TSX:CSCI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cosciens Biopharma Quick Ratio Related Terms
Cosciens Biopharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:CSCI vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cosciens Biopharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (TSX:CSCI) has a Quick Ratio of 0.00 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cosciens Biopharma and its competitors. Over the past decade, Cosciens Biopharma's Quick Ratio has ranged from 0.54 to 19.05. According to the industry distribution chart, Cosciens Biopharma ranks #804 out of 1409 companies in the Biotechnology industry, placing it in the top 57.1%.
Is Cosciens Biopharma's Quick Ratio too high?
Cosciens Biopharma's current Quick Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 19.05. Based on the distribution chart, Cosciens Biopharma ranks #804 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #804 out of 1409 companies for Quick Ratio. This places Cosciens Biopharma in the lower half of its industry. The industry median Quick Ratio is 3.54. Historically, Cosciens Biopharma's own Quick Ratio has ranged from 0.54 to 19.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.54, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Quick Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (TSX:CSCI) is currently considered Modestly Undervalued. The stock's GF Value™ is C$9.68, compared to a current price of C$7.88 — trading 18.6% below its estimated fair value. The current Quick Ratio is 0.00. Cosciens Biopharma's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cosciens Biopharma (TSX:CSCI), the current Quick Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (TSX:CSCI) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of C$7.88 is trading 18.6% below its estimated GF Value™ of C$9.68.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for TSX:CSCI:
Quick Ratio: 0.00
GF Value™: C$9.68 vs. price of C$7.88 (18.6% below fair value)
No single metric tells the full story. See the TSX:CSCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
58GF Score
Get the complete analysis for TSX:CSCI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CSCI has been successfully added to your 
